Gilead Sciences, Inc. GILD

150.93 1.24 0.83% as of 25 Sep
Market cap
$183.2B
P/E
0.0×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Gilead Sciences, Inc. (GILD) P/E ratio

Gilead Sciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (September 2026) to 979× (November 2024) — the current reading is the lowest in ten years.

P/E ratio, daily

Annual

Period P/E ratio Change
FY2025 17.9× (92.63%)
FY2024 243× 1,228.70%
FY2023 18.3× (21.37%)
FY2022 23.3× 58.62%
FY2021 14.7× (97.48%)
FY2020 583× 3,701.51%
FY2019 15.3× 2.90%
FY2018 14.9× (28.85%)
FY2017 20.9× 184.52%
FY2016 7.4× (10.14%)

Quarterly

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 18.8× 4.83%
Dec 2025 17.9× 5.25%
Sep 2025 17.0× (22.30%)
42 more quarters

Against its own ten years

Low 0.0× High 979×
Ten-year median 17.3×
Current reading's percentile 4

P/E ratio against peers

Company P/E ratio
GILD Gilead Sciences, Inc. n/m
NVO Novo Nordisk A/S compare 9.5×
BMY Bristol Myers Squibb Company compare 13.8×
GSK GSK PLC Sponsored ADR compare 15.3×
SNY Sanofi compare 21.5×
NVS Novartis AG compare 21.8×
AZN AstraZeneca PLC compare 24.7×
AMGN Amgen Inc. compare 25.6×
PFE Pfizer Inc. compare 37.7×
Drug Manufacturers General industry median 24.7×
Healthcare sector median 22.7×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on GILD